Optimization of in vitro expansion of macaque CD4+ T cells using anti-CD3 and co-stimulation for autotransfusion therapy

Journal of Medical Primatology

Volumn 35, Issue 4-5, 2006, Pages 178-193

  Onlamoon, Nattawat ^a,b   Hudson, Krystal ^a   Bryan, Patsy ^a   Mayne, Ann E ^a   Bonyhadi, Mark ^c   Berenson, Ron ^c   Sundstrom, Bruce J ^a   Bostik, Pavel ^a   Ansari, Aftab A ^a   Villinger, François ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MAHIDOL UNIVERSITY   (Thailand)

^c CYCLACEL LTD   (United Kingdom)

Author keywords

CD3; CD4T cell; co stimulation; Expansion

Indexed keywords

CASPASE; CD3 ANTIBODY; CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CROSS REACTING ANTIBODY; CYTOKINE; FREE RADICAL; GLUCOSE; PROTEIN BCL 2;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD AUTOTRANSFUSION; CELL CULTURE; CELL LINEAGE; CELL SURVIVAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; FLOW CYTOMETRY; GLUCOSE TRANSPORT; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE TRANSFUSION; MACACA; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD28; ANTIGENS, CD3; CD4-POSITIVE T-LYMPHOCYTES; CELL GROWTH PROCESSES; CROSS REACTIONS; CYTOKINES; DISEASE MODELS, ANIMAL; FLOW CYTOMETRY; IMMUNOPHENOTYPING; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; MACACA MULATTA; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS;

SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 33745945428     PISSN: 00472565     EISSN: 16000684     Source Type: Journal    
DOI: 10.1111/j.1600-0684.2006.00182.x     Document Type: Article

References (53)

1. Akiba H, Takeda K, Kojima Y, Usui Y, Harada N, Yamazaki T, Ma J, Tezuka K, Yagita H, Okumura K: The role of ICOS in the CXCR5+ follicular B helper T cell maintenance in vivo. J Immunol 2005; 175: 2340-8.
2. Allen TM, Telleher AD, Zaunders J, Walker BD: STI and beyond: the prospects of boosting anti-HIV immune responses. Trends Immunol 2002; 23: 456-60.
3. Amara RR, Villinger F, Altman JD, Lydy SL, O'Neil SP, Staprans SI, Montefiori DC, Xu Y, Herndon JG, Wyatt LS, Candido MA, Kozyr NL, Earl PL, Smith JM, Ma HL, Grimm BD, Hulsey ML, McClure HM, McNicholl JM, Moss B, Robinson HL: Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Vaccine 2002; 20: 1949-55.
4. Andersson J, Boasso A, Nilsson J, Zhang R, Shire NJ, Lindback S, Shearer GM, Chougnet CA: The prevalence of regulatory T cells in lymphoid tissue is correlated with viral load in HIV-infected patients. J Immunol 2005; 174: 3143-7.
5. Ansari AA, Mayne AE, Sundstrom JB, Bostik P, Grimm B, Altman JD, Villinger F: Administration of recombinant rhesus interleukin-12 during acute simian immunodeficiency virus (SIV) infection leads to decreased viral loads associated with prolonged survival in SIVmac251-infected rhesus macaques. J Virol 2002; 76: 1731-43.
6. Barnes K, Ingram JC, Porras OH, Barros LF, Hudson ER, Fryer LG, Foufelle F, Carling D, Hardie DG, Baldwin SA: Activation of GLUT1 by metabolic and osmotic stress: Potential involvement of AMP-activated protein kinase (AMPK). J Cell Sci 2002; 115: 2433-42.
7. Brice GT, Riley JL, Villinger F, Mayne A, Hillyer CD, June CH, Ansari AA: Development of an animal model for autotransfusionItherapy: in vitro characterization and analysis of anti-CD3/CD28 expanded cells. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 19: 210-20.
8. Brice GT, Mayne AE, Villinger F, Ansari AA: A novel role for tumor necrosis factor-alpha in regulating susceptibility of activated CD4+ T cells from human and nonhuman primates for distinct coreceptor using lentiviruses. J Acquir Immune Defic Syndr 2000; 24: 10-22.
9. Brodie SJ, Lewinsohn DA, Patterson BK, Jiyamapa D, Krieger J, Corey L, Greenberg PD, Riddell SR: In vivo migration and function of transferred HIV-1-specific cytotoxic T cells. Nat Med 1999; 5: 34-41.
10. Carroll RG, Riley JL, Levine BL, Feng Y, Kaushal S, Ritchey DW, Bernstein W, Weislow OS, Brown CR, Berger EA, June CH, St Louis DC: Differential regulation of HIV-1 fusion cofactor expression by CD28 costimulation of CD4+ T cells. Science 1997; 276: 273-6.
11. Chen HW, Liao CH, Ying C, Chang CJ, Lin CM: Ex vivo expansion of dendritic-cell-activated antigen-specific CD4(+) T cells with anti-CD3/ CD28, interleukin-7, and interleukin-15: Potential for adoptive T cell immunotherapy. Clin Immunol, 2006; 119: 21-31.
12. Coenen JJ, Koenen HJ, Rijssen EV, Hilbrands LB, Joosten I: Rapamycin, and not cyclosporin A, preserves the highly suppressive CD27+ subset of human CD4+CD25+ regulatory T cells. Blood 2006; 107: 1018-23.
13. De Rosa SC, Zaretsky MD, Dubs JG, Roederer M, Anderson M, Green A, Mitra D, Watanabe N, Nakamura H, Tjioe I, Deresinski SC, Moore WA, Ela SW, Parks D, Herzenberg LA: N-acetylcysteine replenishes glutathione in HIV infection. Eur J Clin Invest 2000; 30: 915-29.
14. Deeks SG, Wagner B, Anton PA, Mitsuyasu RT, Scadden DT, Huang C, Macken C, Richman DD, Christopherson C, June CH, Lazar R, Broad DF, Jalali S, Hege KM: A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy. Mol Ther 2002; 5: 788-97.
15. Douek DC, Brenchley JM, Betts MR, Ambrozak DR, Hill BJ, Okamoto Y, Casazza JP, Kuruppu J, Kunstman K, Wolinsky S, Grossman Z, Dybul M, Oxenius A, Price DA, Connors M, Koup RA: HIV preferentially infects HIV-specific CD4+ T cells. Nature 2002; 417: 95-8.
16. Dropulic B, MacGregor RR, Humeau L, Binder G, Lu X, Slepushkin V, Merling R, Pereira M, Slepushkina T, Barnett S, Carroll R, Levine B, Bushman F, June C: Phase I clinical trial demonstrates safety and feasibility of autologous cellular therapy with lentiviral vector modified CD4 T cells expressing anti-HIV antisense in patients with HAART-resistant HIV-1 infection. In: 12th Conference on Retroviruses and Opportunistic Infections, Feb 22-25, 552 (Abstr), 2005.
17. Frauwirth KA, Riley JL, Harris MH, Parry RV, Rathmell JC, Plas DR, Elstrom RL, June CH, Thompson CB: The CD28 signaling pathway regulates glucose metabolism. Immunity 2002; 16: 769-77.
18. Fritsch RD, Shen X, Sims GP, Hathcock KS, Hodes RJ, Lipsky PE: Stepwise differentiation of CD4 memory T cells defined by expression of CCR7 and CD27. J Immunol 2005; 175: 6489-97.
19. Garcia F, Lejeune M, Climent N, Gil C, Alcami J, Morente V, Alos L, Ruiz A, Setoain J, Fumero E, Castro P, Lopez A, Cruceta A, Piera C, Florence E, Pereira A, Libois A, Gonzalez N, Guila M, Caballero M, Lomena F, Joseph J, Miro JM, Pumarola T, Plana M, Gatell JM, Gallart T: Therapeutic immunization with dendritic cells loaded with heat-inactivated autologous HIV-1 in patients with chronic HIV-1 infection. J Infect Dis 2005; 191: 1680-5.
20. Greenwald RJ, Freeman GJ, Sharpe AH: The B7 family revisited. Annu Rev Immunol 2005; 23: 515-48.
21. Jacobson MA, Spritzler J, Landay A, Chan E, Katzenstein D, Schock B, Fox L, Roe J, Kundu S, Pollard R: A Phase I, placebo-controlled trial of multi-dose recombinant human interleukin-12 in patients with HIV infection. AIDS 2002; 16: 1147-54.
22. Kalamasz D, Long SA, Taniguchi R, Buckner JH, Berenson RJ, Bonyhadi M: Optimization of human T-cell expansion ex vivo using magnetic beads conjugated with anti-CD3 and anti-CD28 antibodies. J Immunother 2004; 27: 405-18.
23. Kovacs JA, Imamichi H, Vogel S, Metcalf JA, Dewar RL, Baseler M, Stevens R, Adelsberger J, Lambert L, Davey RT, Jr, Walker RE, Falloon J, Polis MA, Masur H, Lane HC: Effects of intermittent interleukin-2 therapy on plasma and tissue human immunodeficiency virus levels and quasi-species expression. J Infect Dis 2000; 182: 1063-9.
24. Kukidome D, Nishikawa T, Sonoda K, Imoto K, Fujisawa K, Yano M, Motoshima H, Taguchi T, Matsumura T, Araki E: Activation of AMP-activated protein kinase reduces hyperglycemia-induced mitochondrial reactive oxygen species production and promotes mitochondrial biogenesis in human umbilical vein endothelial cells. Diabetes 2006; 55: 120-7.
25. Lederman MM: Immune restoration and CD4+ T-cell function with antiretroviral therapies. AIDS 2001; 15 (Suppl. 2): S11-5.
26. Lee HW, Nam KO, Seo SK, Kim YH, Kang H, Kwon BS: 4-1BB cross-linking enhances the survival and cell cycle progression of CD4 T lymphocytes. Cell Immunol 2003; 223: 143-50.
27. Lee SJ, Myers L, Muralimohan G, Dai J, Qiao Y, Li Z, Mittler RS, Vella AT: 4-1BB and OX40 dual costimulation synergistically stimulate primary specific CD8 T cells for robust effector function. J Immunol 2004; 173: 3002-12.
28. Levine BL, Mosca JD, Riley JL, Carroll RG, Vahey MT, Jagodzinski LL, Wagner KF, Mayers DL, Burke DS, Weislow OS, St Louis DC, June CH: Antiviral effect and ex vivo CD4+ T cell proliferation in HIV-positive patients as a result of CD28 costimulation. Science 1996; 272: 1939-43.
29. Levine BL, Cotte J, Small CC, Carroll RG, Riley JL, Bernstein WB, Van Epps DE, Hardwick RA, June CH: Large-scale production of CD4+ T cells from HIV-1-infected donors after CD3/CD28 costimulation. J Hematother 1998; 7: 437-48.
30. Lieberman J, Skolnik PR, Parkerson GR, III, Fabry JA, Landry B, Bethel J, Kagan J: Safety of autologous, ex vivo-expanded human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte infusion in HIV-infected patients. Blood 1997; 90: 2196-206.
31. Lisziewicz J, Lori F: Structured treatment interruptions in HIV/AIDS therapy. Microbes Infect 2002; 4: 207-14.
32. Lu W, Arraes LC, Ferreira WT, Andrieu JM: Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat Med 2004; 10: 1359-65.
33. Marrack P, Kappler J: Control of T cell viability. Annu Rev Immunol 2004; 22: 765-87.
34. Mitsuyasu RT, Anton PA, Deeks SG, Scadden DT, Connick E, Downs MT, Bakker A, Roberts MR, June CH, Jalali S, Lin AA, Pennathur-Das R, Hege KM: Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects. Blood 2000; 96: 785-93.
35. Miyamoto K, Kingsley CI, Zhang X, Jabs C, Izikson L, Sobel RA, Weiner HL, Kuchroo VK, Sharpe AH: The ICOS molecule plays a crucial role in the development of mucosal tolerance. J Immunol 2005; 175: 7341-7.
36. Moss RB, Jensen FC, Carlo DJ, Wallace MR: The strategy of immunologic control of HIV-1 with structured treatment interruptions (STIs). Curr Drug Targets Infect Disord 2001; 1: 11-7.
37. Munks MW, Mourich DV, Mittler RS, Weinberg AD, Hill AB: 4-1BB and OX40 stimulation enhance CD8 and CD4 T-cell responses to a DNA prime, poxvirus boost vaccine. Immunology 2004; 112: 559-66.
38. van Noesel CJ, Gruters RA, Terpstra FG, Schellekens PT, van Lier RA, Miedema F: Functional and phenotypic evidence for a selective loss of memory T cells in asymptomatic human immunodeficiency virus-infected men. J Clin Invest 1990; 86: 293-9.
39. Oelke M, Krueger C, Schneck JP: Technological advances in adoptive immunotherapy. Drugs Today 2005; 41: 13-21.
40. Riley JL, Carroll RG, Levine BL, Bernstein W, St Louis DC, Weislow OS, June CH: Intrinsic resistance to T cell infection with HIV type 1 induced by CD28 costimulation. J Immunol 1997; 158: 5545-53.
41. Roederer M, Staal FJ, Raju PA, Ela SW, Herzenberg LA: Cytokine-stimulated human immunodeficiency virus replication is inhibited by N-acetyl-L-cysteine. Proc Natl Acad Sci U S A 1990; 87: 4884-8.
42. Seo SK, Choi JH, Kim YH, Kang WJ, Park HY, Suh JH, Choi BK, Vinay DS, Kwon BS: 4-1BB-mediated immunotherapy of rheumatoid arthritis. Nat Med 2004; 10: 1088-94.
43. Smith KA: Low-dose daily interleukin-2Aimmunotherapy: accelerating immune restoration and expanding HIV-specific T-cell immunity without toxicity. AIDS 2001; 15 (Suppl. 2): S28-35.
44. Starck L, Scholz C, Dorken B, Daniel PT: Costimulation by CD137/4-1BB inhibits T cell apoptosis and induces Bcl-xL and c-FLIP(short) via phosphatidylinositol 3-kinase and AKT/protein kinase B. Eur J Immunol 2005; 35: 1257-66.
45. Valdez H, Connick E, Smith KY, Lederman MM, Bosch RJ, Kim RS, St Clair M, Kuritzkes DR, Kessler H, Fox L, Blanchard-Vargas M, Landay A: Limited immune restoration after 3 years' suppression of HIV-1 replication in patients with moderately advanced disease. AIDS 2002; 16: 1859-66.
46. Villinger F, Bucur S, Chikkala NF, Brar SS, Bostik P, Mayne AE, Adams J, Lee ME, Novembre FJ, Gately MK, Ansari AA, Hillyer CD: In vitro and in vivo responses to interleukin 12 are maintained until the late SIV infection stage but lost during AIDS. AIDS Res Hum Retroviruses 2000; 16: 751-63.
47. Villinger F, Brice GT, Mayne AE, Bostik P, Mori K, June CH, Ansari AA: Adoptive transfer of simian immunodeficiency virus (SIV) naive autologous CD4(+) cells to macaques chronically infected with SIV is sufficient to induce long-term nonprogressor status. Blood 2002; 99: 590-9.
48. Villinger F, Miller R, Mori K, Mayne AE, Bostik P, Sundstrom JB, Sugimoto C, Ansari AA: IL-15 is superior to IL-2 in the generation of long-lived antigen specific memory CD4 and CD8 T cells in rhesus macaques. Vaccine 2004; 22: 3510-21.
49. Wang Z, Neville DM: Expression and characterization of recombinant soluble monkey CD3 molecules: Mapping the FN18 polymorphic epitope. Mol Immunol 2004; 40: 1179-88.
50. Wen T, Bukczynski J, Watts TH: 4-1BB ligand-mediated costimulation of human T cells induces CD4 and CD8 T cell expansion, cytokine production, and the development of cytolytic effector function. J Immunol 2002; 168: 4897-906.
51. Yue FY, Kovacs CM, Dimayuga RC, Gu XX, Parks P, Kaul R, Ostrowski MA: Preferential apoptosis of HIV-1-specific CD4+ T cells. J Immunol 2005; 174: 2196-204.
52. Zhang D, Murakami A, Johnson RP, Sui J, Cheng J, Bai J, Marasco WA: Optimization of ex vivo activation and expansion of macaque primary CD4-enriched peripheral blood mononuclear cells for use in anti-HIV immunotherapy and gene therapy strategies. J Acquir Immune Defic Syndr 2003; 32: 245-54.
53. Zheng G, Wang B, Chen A: The 4-1BB costimulation augments the proliferation of CD4+CD25+ regulatory T cells. J Immunol 2004; 173: 2428-34.